Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03912337 · ClinicalTrials.gov registry record · Phase 4
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
A Phase 4 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT03912337 is a Phase 4 study that was terminated before completion, run by Amgen. The registered enrollment target is 29 participants.
The verdict
NCT03912337, a Phase 4 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.
Interventions
- DRUG Placebo
- DRUG Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2021-07-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03912337
The ClinicalTrials.gov registry entry for NCT03912337 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03912337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03912337 about?
NCT03912337 is a clinical study titled "Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine". To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.
What is the current status of trial NCT03912337?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2019-12-04. Estimated completion is 2021-07-28.
What interventions are being tested in trial NCT03912337?
The interventions under investigation include: Placebo (DRUG), Erenumab (DRUG).
Who is sponsoring clinical trial NCT03912337?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.